Skip to Content
Merck
CN

L106

Loxapine succinate salt

solid

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

Empirical Formula (Hill Notation):
C18H18ClN3O · C4H6O4
CAS Number:
Molecular Weight:
445.90
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
EC Number:
248-682-0
MDL number:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Product Name

Loxapine succinate salt, solid

InChI key

YQZBAXDVDZTKEQ-UHFFFAOYSA-N

InChI

1S/C18H18ClN3O.C4H6O4/c1-21-8-10-22(11-9-21)18-14-12-13(19)6-7-16(14)23-17-5-3-2-4-15(17)20-18;5-3(6)1-2-4(7)8/h2-7,12H,8-11H2,1H3;1-2H2,(H,5,6)(H,7,8)

SMILES string

CN(CC1)CCN1C2=NC3=C(C=CC=C3)OC4=C2C=C(Cl)C=C4.OC(CCC(O)=O)=O

form

solid

color

white

solubility

H2O: soluble

originator

Watson

Quality Level

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

D2/D4 dopamine receptor antagonist; 5-HT2A/2B, 5-H7 serotonin receptor antagonist; dibenzoxazepine antipsychotic agent.

Features and Benefits

This compound was developed by Watson. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Tamara Pringsheim et al.
Canadian journal of psychiatry. Revue canadienne de psychiatrie, 56(10), 630-634 (2011-10-22)
To describe the frequency and trends in the use of antipsychotics for adults with schizophrenia in Canada from 2005 to 2009. Analyses were performed on IMS Brogan's Canadian Disease and Therapeutic Index (CDTI). The CDTI is a national physician panel
Joseph Kwentus et al.
Bipolar disorders, 14(1), 31-40 (2012-02-15)
The present study evaluated inhaled loxapine for the acute treatment of agitation in patients with bipolar I disorder. A Phase 3, randomized, double blind, placebo-controlled, parallel group inpatient study was performed at 17 psychiatric research facilities. Agitated patients (N=314) with
D Fiorella et al.
Psychopharmacology, 121(3), 347-356 (1995-10-01)
Investigations conducted over the past 3 decades have demonstrated that serotonergic receptors, specifically the 5-HT2A and 5-HT2C subtypes, play an important role in the behavioral effects of hallucinogenic compounds. The present study was designed to determine the respective significance of
H O Kalkman et al.
British journal of pharmacology, 124(7), 1550-1556 (1998-09-02)
1. The mechanism underlying the anticataleptic properties of the atypical neuroleptic agent, clozapine, has been investigated in the rat. 2.The close structural analogues of clozapine, loxapine (0.1 mg kg(-1) s.c.) and iso-clozapine (1 and 3 mg kg(-1) s.c.) induced catalepsy
Andrea Reed et al.
Drug metabolism letters, 6(1), 26-32 (2012-02-04)
The antipsychotic drugs risperidone, paliperidone, olanzapine, quetiapine, aripiprazole, clozapine, haloperidol, and chlorpromazine have been reported to have various degrees of interaction (substrate or inhibitor) with the multidrug resistance transporter, P-glycoprotein (P-gp). An interaction of the antipsychotic drug loxapine with P-gp

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service